Navigation Links
Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Date:3/17/2008

PRINCETON, N.J., March 17 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today that the following clinical and preclinical abstracts are expected to be the subject of oral or poster presentations at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego:

-- "Dendritic and T cell functions in patients with metastatic hormone-

refractory prostate cancer treated with GVAX immunotherapy for prostate

cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session)

- Oral presentation scheduled for Monday, April 14, 2008 at 1:25 p.m.

-- "CTLA-4 blockade for hormone refractory prostate cancer: dose-dependent

induction of CD8+ T cell activation and clinical responses" (Abstract

#2539, Clinical Immunotherapy Session) - Oral presentation scheduled

for Monday, April 14, 2008 at 1:40 p.m.

-- "Increased doses of an anti-CD30 antibody, MDX-060, results in

prolonged progression free survival in subjects with CD30 positive

lymphoma" (Abstract #5525, Phase 2 and 3 Clinical Trials 3: Blood,

Lung, Brain/CNS and Sarcoma Session) - Poster session scheduled for

Wednesday, April 16, 2008 at 8:00 a.m.

-- "Preclinical development of anti B7-H4 therapeutic antibodies"

(Abstract #4986, Developmental Immunotherapy Session) - Oral

presentation scheduled for Tuesday, April 15, 2008 at 2:25 p.m.

-- "Human antibody conjugates of potential utility for prostate cancer

therapy: a comparison of MGBA conjugates with antibodies targeting a

cell surface target (prostate-specific membrane antigen) and an extra-

cellular target (Mindin/RG1)" (Abstract #4062, Immunoconjugates,

Peptides, and Protein Therapeutics Session) - Poster session scheduled

for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Efficacy and safety of a human anti-CD70 antibody-MGBA conjugate"

(Abstract #4061, Immunoconjugates, Peptides, and Protein Therapeutics

Session) - Poster session scheduled for Tuesday, April 15, 2008 at 8:00

a.m.

-- "Mechanism of activation of a human anti-CD70 antibody-MGBA conjugate

and efficacy in a nude rat model of renal carcinoma" (Abstract #4057,

Immunoconjugates, Peptides, and Protein Therapeutics Session) - Poster

session scheduled for Tuesday, April 15, 2008 at 8:00 a.m.

-- "Ptk7 as a direct and tumor stroma target in multiple solid

malignancies" (Abstract #1526, Targets and Screening Approaches

Session) - Poster session scheduled for Sunday, April 13, 2008 at 1:00

p.m.

Abstracts and information about the AACR and its Annual Meeting may be found at http://www.aacr.org.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
2. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
3. Medarex Announces Completion of Sale of Shares in Genmab A/S
4. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
5. Medarex Announces Election of Marc Rubin as New Board Member
6. Medarex to Present at the UBS Global Life Sciences Conference
7. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
8. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
9. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
10. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
11. Apieron, Inc. Announces FDA Clearance of the Insight(TM) eNO System to Assist Physicians with Patient Asthma Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... 23, 2016 , ... UAS LifeSciences, one of the leading ... UP4™ Probiotics, into Target stores nationwide. The company, which has been manufacturing high ... its list of well-respected retailers. This list includes such fine stores as Whole ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
(Date:6/23/2016)... , June 23, 2016 Houston ... with the Cy-Fair Sports Association to serve as ... the agreement, Houston Methodist Willowbrook will provide sponsorship ... and connectivity with association coaches, volunteers, athletes and ... with the Cy-Fair Sports Association and to bring ...
(Date:6/23/2016)...  The Prostate Cancer Foundation (PCF) is pleased to announce 24 ... for prostate cancer. Members of the Class of 2016 were selected from a ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 Perimeter Surveillance ... Unmanned Systems, Physical Infrastructure, Support & Other Service  ... visiongain offers comprehensive analysis of the global ... will generate revenues of $17.98 billion in 2016. ... Inc, a leader in software and hardware technologies for ...
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing ...  3D medical LCD display is the latest premium product recently added to the range ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... May 16, 2016   EyeLock LLC , a ... the opening of an IoT Center of Excellence in ... expand the development of embedded iris biometric applications. ... of convenience and security with unmatched biometric accuracy, making ... aside from DNA. EyeLock,s platform uses video technology to ...
Breaking Biology News(10 mins):